Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors
Open Access
- 21 June 2025
- journal article
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 27, 101063
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Immune checkpoint inhibitors for cancer and venous thromboembolic eventsEuropean Journal of Cancer, 2021
- Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in EudravigilanceDrug Safety, 2021
- Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic reviewThrombosis Research, 2020
- Cardiovascular Adverse Events Associated With BRAF and MEK InhibitorsJAMA Network Open, 2019
- Mechanism and management of cancer-associated thrombosisJournal of Cardiology, 2018
- What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients’ Quality of Life?Value in Health, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common CancersArchives of internal medicine (1960), 2006
- Malignancies, Prothrombotic Mutations, and the Risk of Venous ThrombosisJAMA, 2005
- Prognosis of Cancers Associated with Venous ThromboembolismNew England Journal of Medicine, 2000